Recent studies have uncovered new cancer therapeutic targets and strategies, including self-assembling antibody-drug conjugates, a dual-action metabolic drug, and a BRAF protein structure. Research also advanced on dendritic cell vaccines, the origins of a rare childhood leukemia, and cancer cachexia treatment.
At the ADA Scientific Sessions, Novo Nordisk's Wegovy pill surpassed 3 million prescriptions within five months, while Structure Therapeutics and AstraZeneca shared mid-stage GLP-1 data targeting a 2029 launch. The US FDA approved TRUQAP as the first targeted treatment for PTEN-deficient metastatic prostate cancer, reducing disease progression risk by 19% in the CAPItello-281 trial. Meanwhile, two major genomic atlas projects—a 4,098-genome infant gut bacteria catalog and Basecamp Research's Trillion Gene Atlas—aim to advance precision probiotics and AI-driven drug discovery, respectively.
C-peptide is described as a key biomarker for beta cell function in type 1 diabetes and a potential surrogate endpoint for drug approval. Current trial endpoints remain difficult for disease-modifying therapies.
Studies on immune checkpoint inhibitor therapy found pretreatment biomarkers strongly predicted checkpoint inhibitor-associated autoimmune diabetes, while hyperglycemia during treatment was common and did not worsen disease progression.
Phase III KEYNOTE-B15 trial demonstrates enfortumab vedotin plus pembrolizumab significantly improves event-free survival and pathologic complete response rates compared with cisplatin-based chemotherapy in muscle-invasive bladder cancer.
New analysis suggests leptin hormone could normalize blood sugar in type 1 diabetes by acting on the brain, potentially offering an alternative to daily insulin injections based on research dating back to 2011.
GLP-1 receptor agonists like semaglutide and liraglutide may improve fertility through metabolic benefits but are not recommended during pregnancy. Current guidance advises discontinuing long-acting agents at least two months before conception.
Soleno Therapeutics provided updates on its VYKAT XR commercial launch for Prader-Willi syndrome, reporting reimbursement progress across nearly 48 Medicaid programs and over 600 prescribers, while European regulatory review continues for approximately 9,500 additional patients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07769138 |
Implementation of Networked Continuous Glucose Monitoring With Telemetry Within the Intensive Care Unit (ICU-TeleCGM) |
NOT_YET_RECRUITING | |
| NCT07696273 |
Miniaturized Breath-based Sensor for the Detection of Hypo- and Hyperglycemia |
RECRUITING | NA |
| NCT07686939 |
Clinical Validation of Continuous Glucose Monitoring in Glycemic Management of Critically Ill Sepsis Patients |
COMPLETED | |
| NCT07669389 |
Effectiveness of a Diabetes Self-Management Program Among Ethnic Minority Elderly in Rural Thailand |
COMPLETED | NA |
| NCT07653048 |
Personality Traits and Biochemical Risk Phenotypes |
RECRUITING | |
| NCT07578090 |
Regional Innovation in Chronic Disease and Elderly Care |
RECRUITING | |
| NCT07574333 |
Effects of Short and Long Courses of Intermittent Hypoxic-Hyperoxic Training in Patients With Type 2 Diabetes Including Elderly |
RECRUITING | NA |
| NCT07510919 |
CGM in Acute Ischemic Stroke |
NOT_YET_RECRUITING | NA |
| NCT07503366 |
Standardized Italian netwoRk Enrolling iNdividuals With Islet-Autoantibodies |
NOT_YET_RECRUITING | |
| NCT07400549 |
Prospective Exploratory Study on the Comprehensive Application Effectiveness of Exercise Prescription Decision Support Tools in the Management of Patients With "Four Highs" (Hypertension, Hyperglycemia, Hyperlipidemia, Hyperuricemia) |
RECRUITING | NA |
